Lanzhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 19, 2021 at 08:30 am
Share
LanZhou Foci Pharmaceutical Co.,Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 386.826 million compared to CNY 328.486 million a year ago. Operating income was CNY 55.888 million compared to CNY 115.446 million a year ago. Net income was CNY 49.549 million compared to CNY 97.551 million a year ago. Basic earnings per share from continuing operations was CNY 0.097 compared to CNY 0.191 a year ago.
LanZhou Foci Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs and large health products. The Companyâs main products are categorized into pills, tablets, granules, syrups, capsules, glue and others, including Liuwei Dihuang pills, Xiaoyao Pill, Xiangsha Yangwei pills, ginseng Gubeng Huanhao pills and other Chinese patent drugs, as well as large health products, such as Ejiao and Ejiao loafs. The Company distributes its products under the brand names Foci, Baolu and Mianshan. The Company is also involved in the cultivation, processing and marketing of Chinese herbal medicine. The Company distributes its products in domestic market and to overseas markets.
LANZHOU FOCI PHARMACEUTICAL CO.,LTD. 
